about
Duffy-null-associated low neutrophil counts influence HIV-1 susceptibility in high-risk South African black womenRole of Education in HIV Clinical Outcomes in a Tuberculosis Endemic SettingRifampicin mono-resistance in Mycobacterium tuberculosis in KwaZulu-Natal, South Africa: a significant phenomenon in a high prevalence TB-HIV regionImpact of an adherence intervention on the effectiveness of tenofovir gel in the CAPRISA 004 trial.Health-related quality of life dynamics of HIV-positive South African women up to ART initiation: evidence from the CAPRISA 002 acute infection cohort studySensitive tenofovir resistance screening of HIV-1 from the genital and blood compartments of women with breakthrough infections in the CAPRISA 004 tenofovir gel trialImpact of antiretroviral therapy on health-related quality of life among South African women in the CAPRISA 002 acute infection study.Effects of introducing Xpert MTB/RIF test on multi-drug resistant tuberculosis diagnosis in KwaZulu-Natal South Africa.HIV prevention in high-risk women in South Africa: condom use and the need for change.Fluidity of HIV-1-specific T-cell responses during acute and early subtype C HIV-1 infection and associations with early disease progression.Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infectionAssociation of TRIM22 with the type 1 interferon response and viral control during primary HIV-1 infectionHIV disease progression in seroconvertors from the CAPRISA 004 tenofovir gel pre-exposure prophylaxis trialChallenges of diagnosing acute HIV-1 subtype C infection in African women: performance of a clinical algorithm and the need for point-of-care nucleic-acid based testingRapid disease progression in HIV-1 subtype C-infected South African women.High incidence of hospital admissions with multidrug-resistant and extensively drug-resistant tuberculosis among South African health care workersThe neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infectionInterleukin-10 promoter polymorphisms influence HIV-1 susceptibility and primary HIV-1 pathogenesisHIV-positive status disclosure in patients in care in rural South Africa: implications for scaling up treatment and prevention interventionsStabilizing HIV prevalence masks high HIV incidence rates amongst rural and urban women in KwaZulu-Natal, South Africa.Adherence in the treatment of patients with extensively drug-resistant tuberculosis and HIV in South Africa: a prospective cohort study.Association of polymorphisms in the LEDGF/p75 gene (PSIP1) with susceptibility to HIV-1 infection and disease progression.South African HIV-1 subtype C transmitted variants with a specific V2 motif show higher dependence on α4β7 for replication.Randomized Cross-Sectional Study to Compare HIV-1 Specific Antibody and Cytokine Concentrations in Female Genital Secretions Obtained by Menstrual Cup and Cervicovaginal Lavage.Differences in HIV type 1 neutralization breadth in 2 geographically distinct cohorts in Africa.Extensively drug-resistant tuberculosis in women, KwaZulu-Natal, South Africa.Primary Capreomycin Resistance Is Common and Associated With Early Mortality in Patients With Extensively Drug-Resistant Tuberculosis in KwaZulu-Natal, South Africa.Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness.Risk Factors for HIV Acquisition in High Risk Women in a Generalised Epidemic Setting.High Burden of Human Papillomavirus (HPV) Infection among Young Women in KwaZulu-Natal, South AfricaRestoration of CD4+ Responses to Copathogens in HIV-Infected Individuals on Antiretroviral Therapy Is Dependent on T Cell Memory Phenotype.Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 InfectionGenital inflammation and the risk of HIV acquisition in womenPreservation HIV-1-specific IFNγ+ CD4+ T-cell responses in breakthrough infections after exposure to tenofovir gel in the CAPRISA 004 microbicide trialCAPRISA 004 tenofovir microbicide trial: no impact of tenofovir gel on the HIV transmission bottleneck.HIV incidence in young girls in KwaZulu-Natal, South Africa--public health imperative for their inclusion in HIV biomedical intervention trials.Innate Antibacterial Activity in Female Genital Tract Secretions Is Associated with Increased Risk of HIV Acquisition.APOBEC3G expression is dysregulated in primary HIV-1 infection and polymorphic variants influence CD4+ T-cell counts and plasma viral load.Symptomatic vaginal discharge is a poor predictor of sexually transmitted infections and genital tract inflammation in high-risk women in South Africa.Lower concentrations of chemotactic cytokines and soluble innate factors in the lower female genital tract associated with the use of injectable hormonal contraceptive.
P50
Q24613572-37E2B47B-2886-4C66-BC54-4A358FC68DA4Q25017374-CC8380E1-B108-4A82-A401-A1B0C4967037Q28534875-0DB4B59D-1C80-49D7-93E9-00DB46BA087EQ33570985-64A0A156-1D38-4B44-A7F4-CD0CD62A6653Q33610865-33F1BD9F-17DE-4C20-975B-FC169354983AQ33684387-3E200306-7A87-434F-AF38-78AB7ECDBB10Q34021927-CA463F26-39FC-4EE2-8B15-378C10B8E4FEQ34076574-2E9747EF-4372-41A0-940A-F966F0426D47Q34170153-D9BAE8DC-19DA-4066-9B88-509DABBED5A9Q34295981-AEBFA28D-261E-4A17-BBF2-DA2F6DD5F96EQ34300812-64B93B57-1BB9-4E43-82AE-0294A185F84AQ34458011-D3BB05F1-2BB3-4A0F-A9A6-FFA7A46F14E1Q34674930-5F8E1BA8-0C91-456D-8A54-00E29550D1CFQ34706934-2D3808DD-68E7-44DD-890D-D603A8ACA6F4Q34736181-2E2A7B5D-BD56-4A5A-9C4C-7EC6CE4D91E8Q34779982-A7F4F13D-6D6A-43AC-8AA5-95A5FD52C5D8Q35076717-2AFC5A05-6AFA-4E1B-8557-9B02156A068DQ35109877-6FD8D868-5D18-4A5E-9119-E15B75586C90Q35133519-867BAEAF-586B-4452-ABE7-DE982AFE3FFAQ35165313-8BF599AF-7F44-4123-BAD0-B70AA06DDBD4Q35538913-93DD8E0E-8D31-4F9A-9873-D167EA59647DQ35600919-461665E0-0444-4E83-9D69-70C69A53C4E0Q35672336-C5E3180B-880C-4E93-9D92-85644C36ACE0Q35683986-EA3D8CF0-2A0F-490B-B4B2-EB565A66E63BQ35715634-104FB4FB-86DA-4540-8F3F-31B5C0351D78Q35847593-E7A96E70-0092-448A-AC50-52A9A20B5FDBQ35850402-D5C9CA71-FF9C-470A-9BD7-31C27F007CD0Q35861437-1308E8D7-E396-443B-AD0C-FABDBFCFC631Q35862772-83B74B3D-B30D-4318-9277-B230206BA941Q35898044-E628598A-FBEE-4472-9331-09E4E1604076Q35988556-5A956C2E-7740-498D-9963-22F315D407A1Q36034465-7ACA2C65-9CD1-4DF7-8785-13E4E0DAFC6BQ36049017-293FE5F7-9E47-49C6-8412-CCBFF89629A3Q36053228-7F26EF7C-6075-4840-B28F-B5789D1BD39DQ36154165-D2728E96-7F7E-4649-8AEA-C0BD37C2D044Q36285257-57A5D974-EACC-4B3D-B5CB-B41F32A4B147Q36294689-9471778B-645B-4C0A-A1D9-CBA12BF220FBQ36316091-93144F62-A7F5-428D-89FF-215A9FABF8F3Q36376181-7AFF8B8D-F012-4567-B180-E8A21E45FF04Q36654106-8F1E15CE-2476-44CA-A852-3B67172D74BD
P50
name
Lise Werner
@en
Lise Werner
@nl
type
label
Lise Werner
@en
Lise Werner
@nl
prefLabel
Lise Werner
@en
Lise Werner
@nl